Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
over 50% of patients achieved 20 to 25% weight reduction thresholds at 176 weeks Semaglutide 2.4 mg: Up to 13.9% weight loss at 68 weeks Liraglutide 3.0 mg: Approximately 5.8% weight loss at 26 weeks Retatrutide (investigational triple agonist): Up to 22.1% weight loss at 48 weeks A meta-analysis of 47 randomized controlled trials confirmed a mean weight reduction of 4.57 kg, BMI reduction of 2.07 kg/m2, and waist circumference reduction of 4.55 cm versus placebo across all GLP-1 receptor agonists
Konopka, A
Research-use-only catalogue Continue to the product record
To pull the COA, email [email protected] from the address used at checkout, with your order number
US$ 26.83
US$ 23.00
US$ 20.41
US$ 24.09
US$ 22.56
